person · Reporting owner
Polymeropoulos Mihael Hristos
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director · President and CEO · Chairman of the Board | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,704,496 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 156,235 · Balance 2,704,496 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 51,049 | $13.19 | $673,305.68 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296,234 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 61,520 | $8.75 | $538,300.00 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,347,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,817 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · derivative · entry 7 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,183 Underlying: Common Stock · 41,817 shares Expires 2020-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in 48 equal monthly installments from the date of grant. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 35,053 | $12.88 | $451,359.95 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,285,763 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 41,817 | $8.75 | $365,898.75 |
DisclosureSEC source: 0001209191-20-063474 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,152 | $10.98 | $56,544.23 |
DisclosureSEC source: 0001209191-20-016204 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,999 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.80 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 10,428 | $10.57 | $110,211.45 |
DisclosureSEC source: 0001209191-20-016204 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,151 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:03 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-20-014127 · doc4.xml · derivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-02-25 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:03 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-014127 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294,579 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 9,467 | $16.00 | $151,492.83 |
DisclosureSEC source: 0001209191-20-002031 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,579 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to a written election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.81 to $16.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 85,801 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · derivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,801 shares Expires 2019-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in 48 equal monthly installments from the date of grant. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 70,036 | $16.98 | $1,189,351.35 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,244,046 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 16, 2019 as reflected in this Form 4. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 85,801 | $10.65 | $913,780.65 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 89,199 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · derivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,801 Underlying: Common Stock · 89,199 shares Expires 2019-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in 48 equal monthly installments from the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 72,373 | $16.92 | $1,224,377.46 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,281 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 16, 2019 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.55 to $17.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 89,199 | $10.65 | $949,969.35 |
DisclosureSEC source: 0001209191-19-060380 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 79,019 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · derivative · entry 9 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,019 shares Expires 2019-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests each month with respect to 2.0833% of the aggregate option share total. Read SEC document |
| May 21, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 72,872 | $15.34 | $1,117,951.21 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,455 F3 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire May 21, 2019 as reflected in this Form 4. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.92 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| May 21, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 79,019 | $12.55 | $991,688.45 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 73,608 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · derivative · entry 8 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,019 Underlying: Common Stock · 73,608 shares Expires 2019-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests each month with respect to 2.0833% of the aggregate option share total. Read SEC document |
| May 20, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 67,418 | $15.12 | $1,019,083.75 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,308 F3 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire May 21, 2019 as reflected in this Form 4. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| May 20, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 73,608 | $12.55 | $923,780.40 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 97,373 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · derivative · entry 7 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,627 Underlying: Common Stock · 97,373 shares Expires 2019-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests each month with respect to 2.0833% of the aggregate option share total. Read SEC document |
| May 17, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 77,225 | $15.56 | $1,201,690.50 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,118 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy a portion of the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire May 21, 2019 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.38 to $16.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 17, 2019 Filed May 21, 2019 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 97,373 | $12.55 | $1,222,031.15 |
DisclosureSEC source: 0001209191-19-031781 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,276,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 22:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 38,166 | $19.41 | $740,802.06 |
DisclosureSEC source: 0001209191-19-015746 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178,970 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 6,500 | $20.22 | $131,423.50 |
DisclosureSEC source: 0001209191-19-015746 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,136 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:22 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-19-014978 · doc4.xml · derivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2029-02-26 F2 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments from the date of grant, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:22 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014978 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,636 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2020, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 4,447 | $26.04 | $115,804.33 |
DisclosureSEC source: 0001209191-19-001979 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,636 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,056 | $26.93 | $82,310.30 |
DisclosureSEC source: 0001209191-19-001979 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,168,083 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,733 | $26.32 | $203,548.03 |
DisclosureSEC source: 0001209191-19-001979 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171,139 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.87 to $26.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 24, 2018 Filed Jan 4, 2019 21:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001979 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178,872 F1 · kind: Represents a gift to a charitable organization. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 60,966 | $18.72 | $1,141,003.08 |
DisclosureSEC source: 0001209191-18-015887 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,182,872 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.30 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001209191-18-015887 · doc4.xml · derivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-02-27 F4 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-015887 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243,838 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · derivative · entry 11 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F14 · derivative.exercise_date: The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F12 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · derivative · entry 10 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F13 · derivative.exercise_date: The RSUs vest in four (4) equal annual installments beginning January 1, 2016, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F12 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · derivative · entry 9 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F11 · derivative.exercise_date: The RSUs vest in four (4) equal annual installments beginning January 1, 2015, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F12 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · derivative · entry 8 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2018-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vested in 48 equal monthly installments beginning on February 4, 2008. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 21,535 | $15.30 | $329,399.36 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 7 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183,838 F9 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: Each RSU was previously reported on Table II on a Form 4 filed with the SEC on February 17, 2016. F5 · price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F7 · balance_after: Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Each RSU was previously reported on Table II on a Form 4 filed with the SEC on December 5, 2014. F5 · price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. F7 · balance_after: Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Each Restricted Stock Unit ("RSU") was previously reported on Table II on a Form 4 filed with the Securities and Exchange Commission ("SEC") on December 4, 2013. F5 · price: Each RSU represents a contingent right to receive a share of the Issuer's Common Stock. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 170,225 | $15.30 | $2,603,727.56 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,623 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire January 3, 2018 as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 250,000 | $5.76 | $1,440,000.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 4, 2018 22:13 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002064 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,848 F1 · kind: Represents a gift to a charitable organization. F1 · timeliness: Represents a gift to a charitable organization. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:33 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001209191-17-017806 · doc4.xml · derivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-02-28 F4 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments beginning March 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each monthly vesting date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:33 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantRestricted Stock Unit | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-017806 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041,848 F1 · shares: 125,000 of the shares subject to this Restricted Stock Unit ("RSU") shall vest on March 1, 2018 and 75,000 of the shares subject to this RSU shall vest on March 1, 2019, provided Reporting Person remains continuously employed by the Issuer through each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F2 · price: Each RSU represents a contingent right to receive a share of the Issuer's common stock. F3 · balance_after: Reflects a gift of 9,000 shares as set forth on the Reporting Person's Form 5 filed on February 6, 2017. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · derivative · entry 9 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.